Skip to main content

Advertisement

SpringerLink
Log in

In vitro activity of omadacycline against pathogens isolated from Mainland China during 2017–2018

  • Original Article
  • Published:
European Journal of Clinical Microbiology & Infectious Diseases Aims and scope Submit manuscript

Abstract

Antibiotic resistance of bacterial pathogens isolated in China is a major concern. Omadacycline is a novel tetracycline derivative that has been approved for use in skin infections and community-acquired pneumonia. This study was conducted to determine the in vitro activity of omadacycline against a large collection of patient isolate medical centers across Mainland China. A total of 1041 recent clinical isolates are obtained from patients hospitalized in 29 provinces and municipalities across China. The in vitro activity of omadacycline and comparator agents was assessed using the microbroth dilution methodology. Omadacycline was active against methicillin-susceptible and -resistant Staphylococcus aureus with MIC90 values of 0.25 and 1 mg/L, respectively. All isolates of Enterococcus faecalis and Enterococcus faecium, including vancomycin-resistant isolates, were inhibited by ≤ 0.25 mg/L of omadacycline. It was active against Streptococcus pneumoniae irrespective of susceptibility to penicillin or macrolides (MIC90 =0.12 mg/L). The minimum inhibitory concentration (MIC) distribution of omadacycline was nearly identical against (extended-spectrum beta-lactamases) ESBL-positive, ESBL-negative, and carbapenemase-producing Escherichia coli (MIC90 = 4 mg/L). Omadacycline also showed good activity against Acinetobacter baumannii, inhibiting all isolates at ≤ 8 mg/L. Against Hemophilus influenzae and Moraxella catarrhalis, the MICs of omadacycline were low and not influenced by the presence of β-lactamase. Overall, the activity of omadacycline was very good against isolates commonly associated with skin infections and pneumonia, and the susceptibility of Chinese isolates was similar to that reported for these pathogens from large surveillance studies outside China. This suggests that omadacycline could be an option for treatment of these infections in Chinese patients.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

Similar content being viewed by others

Data availability

Data can be provided upon request.

References

  1. Karlowsky JA, Steenbergen J, Zhanel GG (2019) Microbiology and preclinical review of omadacycline. Clin Infect Dis 69(Supplement_1):S6–S15. https://doi.org/10.1093/cid/ciz395

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  2. Heidrich CG, Mitova S, Schedlbauer A, Connell SR, Fucini P, Steenbergen JN, Berens C (2016) The novel aminomethylcycline omadacycline has high specificity for the primary tetracycline-binding site on the bacterial ribosome. Antibiotics (Basel) 5(4). https://doi.org/10.3390/antibiotics5040032

  3. Huband MD, Pfaller MA, Shortridge D, Flamm RK (2019) Surveillance of omadacycline activity tested against clinical isolates from the United States and Europe: results from the SENTRY Antimicrobial Surveillance Programme, 2017. J Glob Antimicrob Resist 19:56–63. https://doi.org/10.1016/j.jgar.2019.02.017

    Article  PubMed  Google Scholar 

  4. Stapert L, Wolfe C, Shinabarger D, Marra A, Pillar C (2018) In vitro activities of omadacycline and comparators against anaerobic bacteria. Antimicrob Agents Chemother 62(4). https://doi.org/10.1128/aac.00047-18

  5. O'Riordan W, Green S, Overcash JS, Puljiz I, Metallidis S, Gardovskis J, Garrity-Ryan L, Das AF, Tzanis E, Eckburg PB, Manley A, Villano SA, Steenbergen JN, Loh E (2019) Omadacycline for acute bacterial skin and skin-structure infections. N Engl J Med 380(6):528–538. https://doi.org/10.1056/NEJMoa1800170

    Article  CAS  PubMed  Google Scholar 

  6. O'Riordan W, Cardenas C, Shin E, Sirbu A, Garrity-Ryan L, Das AF, Eckburg PB, Manley A, Steenbergen JN, Tzanis E, McGovern PC, Loh E (2019) Once-daily oral omadacycline versus twice-daily oral linezolid for acute bacterial skin and skin structure infections (OASIS-2): a phase 3, double-blind, multicentre, randomised, controlled, non-inferiority trial. Lancet Infect Dis 19(10):1080–1090. https://doi.org/10.1016/s1473-3099(19)30275-0

    Article  CAS  PubMed  Google Scholar 

  7. Stets R, Popescu M, Gonong JR, Mitha I, Nseir W, Madej A, Kirsch C, Das AF, Garrity-Ryan L, Steenbergen JN, Manley A, Eckburg PB, Tzanis E, McGovern PC, Loh E (2019) Omadacycline for community-acquired bacterial pneumonia. N Engl J Med 380(6):517–527. https://doi.org/10.1056/NEJMoa1800201

    Article  CAS  PubMed  Google Scholar 

  8. Pfaller MA, Rhomberg PR, Huband MD, Flamm RK (2018) Activity of omadacycline tested against Enterobacteriaceae causing urinary tract infections from a global surveillance program (2014). Diagn Microbiol Infect Dis 91(2):179–183. https://doi.org/10.1016/j.diagmicrobio.2018.01.019

    Article  CAS  PubMed  Google Scholar 

  9. Pfaller MA, Rhomberg PR, Huband MD, Flamm RK (2018) Activity of omadacycline tested against Streptococcus pneumoniae from a global surveillance program (2014). Diagn Microbiol Infect Dis 90(2):143–147. https://doi.org/10.1016/j.diagmicrobio.2017.10.010

    Article  CAS  PubMed  Google Scholar 

  10. CLSI (2018) M07-A11 Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically, Tenth edn. Clinical and Laboratory Standards Institute, Wayne

    Google Scholar 

  11. CLSI (2020) M100-S30 Performance standards for antimicrobial susceptibility testing. Clinical and Laboratory Standards Institute, Wayne, PA

  12. Yin D, Wu S, Yang Y, Shi Q, Dong D, Zhu D, Hu F (2019) Results from the China Antimicrobial Surveillance Network (CHINET) in 2017 of the in vitro activities of ceftazidime-avibactam and ceftolozane-tazobactam against clinical isolates of Enterobacteriaceae and Pseudomonas aeruginosa. Antimicrob Agents Chemother 63(4):e02431–e02418. https://doi.org/10.1128/aac.02431-18

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  13. Yezli S, Li H (2012) Antibiotic resistance amongst healthcare-associated pathogens in China. Int J Antimicrob Agents 40(5):389–397. https://doi.org/10.1016/j.ijantimicag.2012.07.009

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  14. Qiao M, Ying G-G, Singer AC, Zhu Y-G (2018) Review of antibiotic resistance in China and its environment. Environ Int 110:160–172. https://doi.org/10.1016/j.envint.2017.10.016

    Article  CAS  Google Scholar 

  15. Liu Y-Y, Wang Y, Walsh TR, Yi L-X, Zhang R, Spencer J, Doi Y, Tian G, Dong B, Huang X, Yu L-F, Gu D, Ren H, Chen X, Lv L, He D, Zhou H, Liang Z, Liu J-H, Shen J (2016) Emergence of plasmid-mediated colistin resistance mechanism MCR-1 in animals and human beings in China: a microbiological and molecular biological study. Lancet Infect Dis 16(2):161–168. https://doi.org/10.1016/S1473-3099(15)00424-7

    Article  CAS  PubMed  Google Scholar 

  16. Zhang QQ, Ying GG, Pan CG, Liu YS, Zhao JL (2015) Comprehensive evaluation of antibiotics emission and fate in the river basins of China: source analysis, multimedia modeling, and linkage to bacterial resistance. Environ Sci Technol 49(11):6772–6782. https://doi.org/10.1021/acs.est.5b00729

    Article  CAS  PubMed  Google Scholar 

  17. Zhang R, Eggleston K, Rotimi V, Zeckhauser RJ (2006) Antibiotic resistance as a global threat: evidence from China, Kuwait and the United States. Glob Health 2(1):6. https://doi.org/10.1186/1744-8603-2-6

    Article  Google Scholar 

  18. Zhen X, Stålsby Lundborg C, Sun X, Hu X, Dong H (2019) The clinical and economic impact of antibiotic resistance in China: a systematic review and meta-analysis. Antibiotics 8(3):115. https://doi.org/10.3390/antibiotics8030115

    Article  PubMed Central  Google Scholar 

  19. Fluit AC, van Gorkum S, Vlooswijk J (2019) Minimal inhibitory concentration of omadacycline and doxycycline against bacterial isolates with known tetracycline resistance determinants. Diagn Microbiol Infect Dis 94(1):78–80. https://doi.org/10.1016/j.diagmicrobio.2018.11.010

    Article  CAS  PubMed  Google Scholar 

  20. Macone AB, Caruso BK, Leahy RG, Donatelli J, Weir S, Draper MP, Tanaka SK, Levy SB (2014) In vitro and in vivo antibacterial activities of omadacycline, a novel aminomethylcycline. Antimicrob Agents Chemother 58(2):1127–1135. https://doi.org/10.1128/aac.01242-13

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  21. NUZYRA (omadacycline) prescribing information. (2019). https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/209816_209817lbl.pdf.

  22. Carvalhaes CG, Huband MD, Reinhart HH, Flamm RK, Sader HS (2019) Antimicrobial activity of omadacycline tested against clinical bacterial isolates from hospitals in Mainland China, Hong Kong, and Taiwan: results from the SENTRY Antimicrobial Surveillance Program (2013 to 2016). Antimicrob Agents Chemother 63(3):e02262–e02218. https://doi.org/10.1128/aac.02262-18

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  23. Chen CJ, Huang YC (2014) New epidemiology of Staphylococcus aureus infection in Asia. Clin Microbiol Infect 20(7):605–623. https://doi.org/10.1111/1469-0691.12705

    Article  CAS  PubMed  Google Scholar 

  24. Du J, Chen C, Ding B, Tu J, Qin Z, Parsons C, Salgado C, Cai Q, Song Y, Bao Q, Zhang L, Pan J, Wang L, Yu F (2011) Molecular characterization and antimicrobial susceptibility of nasal Staphylococcus aureus isolates from a Chinese medical college campus. PLoS One 6(11):e27328. https://doi.org/10.1371/journal.pone.0027328

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  25. Wu D, Wang Q, Yang Y, Geng W, Wang Q, Yu S, Yao K, Yuan L, Shen X (2010) Epidemiology and molecular characteristics of community-associated methicillin-resistant and methicillin-susceptible Staphylococcus aureus from skin/soft tissue infections in a children’s hospital in Beijing, China. Diagn Microbiol Infect Dis 67(1):1–8. https://doi.org/10.1016/j.diagmicrobio.2009.12.006

    Article  CAS  PubMed  Google Scholar 

Download references

Code availability

Not applicable.

Funding

This study was funded in part by National Mega-project for Innovative Drugs (2019ZX09721001-006-004) and CHINET Antimicrobial Surveillance Network (grant WI207259). It was also funded by Zai Laboratory Inc., Shanghai, China.

Author information

Author notes

  1. Dong Dong and Yonggui Zheng contributed equally to this work.

Authors and Affiliations

  1. Institute of Antibiotics, Huashan Hospital, Fudan University, 12 M. Wulumuqi Rd., Shanghai, 200040, People’s Republic of China

    Dong Dong, Yonggui Zheng, Yan Guo, Yang Yang, Shi Wu, Demei Zhu & Fupin Hu

  2. Key Laboratory of Clinical Pharmacology of Antibiotics, Ministry of Health, Shanghai, China

    Dong Dong, Yonggui Zheng, Yan Guo, Yang Yang, Shi Wu, Demei Zhu & Fupin Hu

  3. Laboratory Medicine, First Hospital of Quanzhou city, QuanZhou, Fujian, China

    Qingqing Chen

  4. Zai Laboratory Inc, Shanghai, China

    Daniel Deng & Harald Reinhart

  5. Antimicrobial Development Specialists, LLC, Nyack, NY, USA

    Patricia A. Bradford

Authors
  1. Dong Dong
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Yonggui Zheng
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Qingqing Chen
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Yan Guo
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Yang Yang
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Shi Wu
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Demei Zhu
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Daniel Deng
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Patricia A. Bradford
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Harald Reinhart
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. Fupin Hu
    View author publications

    You can also search for this author in PubMed Google Scholar

Contributions

All authors made substantial contributions to the conception or design of the work.

Corresponding author

Correspondence to Fupin Hu.

Ethics declarations

Conflict of interest

Antimicrobial development specialists, LLC, was contracted to during 2019 to perform services for Boston Pharma, Carb-X, Colgate Palmolive, ContraFect Corp., Emergent Biosciences, Entasis Therapeutics, EXDA, Nabriva, NacuGen, Novartis, RecreoPharma, Sihuan Pharmaceutical, SuperTrans Medical, Tetraphase, Theravance, University of Waterloo, Wellcome Trust, X-Biotix, and Zai Labs.

Ethical approval

This study was approved by the Institutional Review Board of Huashan Hospital, Fudan University (Number: 2018-349).

Consent to participate

Not applicable.

Additional information

Publisher’s note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Dong, D., Zheng, Y., Chen, Q. et al. In vitro activity of omadacycline against pathogens isolated from Mainland China during 2017–2018. Eur J Clin Microbiol Infect Dis 39, 1559–1572 (2020). https://doi.org/10.1007/s10096-020-03877-w

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10096-020-03877-w

Keywords

Search

Navigation